Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P. Ludwig H, et al. Among authors: touzeau c. Lancet Oncol. 2023 Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6. Lancet Oncol. 2023. PMID: 37269857 Free article. Review.
Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P. Lodé L, et al. Among authors: touzeau c. Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. Br J Haematol. 2013. PMID: 23862718 Free article. No abstract available.
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, Thomaré P, Mahé B, Touzeau C, Moreau P. Lok A, et al. Among authors: touzeau c. Haematologica. 2014 Mar;99(3):e33-4. doi: 10.3324/haematol.2013.100396. Epub 2014 Feb 14. Haematologica. 2014. PMID: 24532044 Free PMC article. No abstract available.
Elotuzumab for the treatment of multiple myeloma.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Future Oncol. 2014 May;10(6):949-56. doi: 10.2217/fon.14.56. Future Oncol. 2014. PMID: 24941981 Review.
New data on subcutaneous bortezomib.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Acta Haematol. 2015;133(1):26-8. doi: 10.1159/000362639. Epub 2014 Jul 1. Acta Haematol. 2015. PMID: 24993571 No abstract available.
Multiple myeloma: from front-line to relapsed therapies.
Moreau P, Touzeau C. Moreau P, et al. Among authors: touzeau c. Am Soc Clin Oncol Educ Book. 2015:e504-11. doi: 10.14694/EdBook_AM.2015.35.e504. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993216 Free article. Review.
How I treat extramedullary myeloma.
Touzeau C, Moreau P. Touzeau C, et al. Blood. 2016 Feb 25;127(8):971-6. doi: 10.1182/blood-2015-07-635383. Epub 2015 Dec 17. Blood. 2016. PMID: 26679866 Free article. Review.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Moreau P, et al. Among authors: touzeau c. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. N Engl J Med. 2016. PMID: 27119237 Free article. Clinical Trial.
172 results